EP4328314A3 — Lipid nanoparticle methods and compositions for producing engineered erythroid cells
Assigned to Tessera Therapeutics Inc · Expires 2024-03-20 · 2y expired
What this patent protects
Carriers such as lipid nanoparticles are useful for delivering payloads (such as RNA, DNA, proteins, or small molecules) to cells such as erythroid cells. This disclosure provides improved carriers that comprise a targeting agent that binds a cell surface receptor. In some embodi…
USPTO Abstract
Carriers such as lipid nanoparticles are useful for delivering payloads (such as RNA, DNA, proteins, or small molecules) to cells such as erythroid cells. This disclosure provides improved carriers that comprise a targeting agent that binds a cell surface receptor. In some embodiments, the cell surface receptor is one that undergoes a high rate of endocytosis.
Drugs covered by this patent
- Onpattro (PATISIRAN SODIUM) · Alnylam Pharmaceuticals
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.